Filtered By:
Source: Journal of Drugs in Dermatology
This page shows you your search results in order of relevance. This is page number 19.
Order by Relevance | Date
Total 922 results found since Jan 2013.
Commonly Used Over the Counter Therapies for Hair Growth in Skin of Color: An Evidenced-Based Review
CONCLUSION: This information will be exceedingly useful for physicians so they may relay accurate evidence on these haircare practices to their skin of color patients. J Drugs Dermatol. 2021;20(7):726-731. doi:10.36849/JDD.5689.PMID:34231986 | DOI:10.36849/JDD.5689
Source: Journal of Drugs in Dermatology - July 7, 2021 Category: Dermatology Authors: Melissa R Laughter Jaclyn B Anderson Nkemjika Ugonabo Zainab Mohammodu Mona Sadeghpour Jerry Shapiro Kristen Lo Sicco Source Type: research
Antihistamines in Psoriasis
J Drugs Dermatol. 2021 Aug 1;20(8):844-847. doi: 10.36849/JDD.5966.ABSTRACTPsoriasis is polygenic, interleukin (IL)-17 and IL-23 driven chronic relapsing inflammatory multisystem disease caused by a complex interplay of endogenous and environmental factors. The most common and distressing symptom in psoriasis is itch, adding significantly to the burden of disease. Although histamine has historically not been considered a key itch mediator in psoriasis, there is some evidence from the literature that antihistamines may be effective to reduce itch in psoriasis. This review focuses on the role of antihistamines in the managem...
Source: Journal of Drugs in Dermatology - August 16, 2021 Category: Dermatology Authors: Swathi Shivakumar Simon M Mueller Paul S Yamauchi Jeffrey M Weinberg Leon Kircik Jacek C Szepietowski Mohamad Goldust Source Type: research
Review of Apremilast Combination Therapies in the Treatment of Moderate to Severe Psoriasis
J Drugs Dermatol. 2021 Aug 1;20(8):837-843. doi: 10.36849/JDD.5845.ABSTRACTPsoriasis is a chronic inflammatory skin condition resulting from the dysregulation of cytokines. Apremilast, an oral phosphodiesterase-4 inhibitor is approved by the Federal Drug Administration (FDA) for the treatment of moderate to severe plaque psoriasis in patients who are eligible for phototherapy or systemic therapy. The drug increases cyclic adenosine monophosphate, cAMP, modulating the expression of pro-inflammatory cytokines. This review aims to explore and categorize current literature describing the efficacy and safety profile of the addi...
Source: Journal of Drugs in Dermatology - August 16, 2021 Category: Dermatology Authors: Mirjana G Ivanic Akshitha Thatiparthi Shikha Walia Wilson Liao Jashin J Wu Source Type: research
Commonly Used Over the Counter Therapies for Hair Growth in Skin of Color: An Evidenced-Based Review
CONCLUSION: This information will be exceedingly useful for physicians so they may relay accurate evidence on these haircare practices to their skin of color patients. J Drugs Dermatol. 2021;20(7):726-731. doi:10.36849/JDD.5689.PMID:34231986 | DOI:10.36849/JDD.5689
Source: Journal of Drugs in Dermatology - July 7, 2021 Category: Dermatology Authors: Melissa R Laughter Jaclyn B Anderson Nkemjika Ugonabo Zainab Mohammodu Mona Sadeghpour Jerry Shapiro Kristen Lo Sicco Source Type: research
Antihistamines in Psoriasis
J Drugs Dermatol. 2021 Aug 1;20(8):844-847. doi: 10.36849/JDD.5966.ABSTRACTPsoriasis is polygenic, interleukin (IL)-17 and IL-23 driven chronic relapsing inflammatory multisystem disease caused by a complex interplay of endogenous and environmental factors. The most common and distressing symptom in psoriasis is itch, adding significantly to the burden of disease. Although histamine has historically not been considered a key itch mediator in psoriasis, there is some evidence from the literature that antihistamines may be effective to reduce itch in psoriasis. This review focuses on the role of antihistamines in the managem...
Source: Journal of Drugs in Dermatology - August 16, 2021 Category: Dermatology Authors: Swathi Shivakumar Simon M Mueller Paul S Yamauchi Jeffrey M Weinberg Leon Kircik Jacek C Szepietowski Mohamad Goldust Source Type: research
